NEW YORK, Jan. 19, 2016 /PRNewswire/ -- The market for molecular histology and cytology technologies exceeded 2.5 billion dollars, according to Kalorama Information. The healthcare market research said advanced technologies to study tissues and cell are routinely used in cancer testing, an area of testing with higher-than-average revenue growth rates. The finding was made in the firm's report The Market for Molecular Histology and Cytology.
Histology is the study of genetic and protein markers in tissues and cytology involves the study of cells. Fluids such as cervical, sputum and joint and pieces of tissue that have been biopsied or surgically removed are processed, placed on glass slides, and stained to characterize targeted cellular constructions, tissue morphology and cell components. The stained slides are read by technologists using microscopy. Pathologists read slides with suspicious or aberrant cells. Recently digital microscopy has automated slide reading and analysis. The tests are used primarily to test biopsied tissue for cancer; cervical fluid for sexually transmitted diseases and HPV; and circulating tumor cells.
The report provides an overview and market analysis for the following testing technologies: Molecular HPV Testing, in situ hybridization, flow cytometry and CTCs. In situ hybridization and more specifically fluorescent in situ hybridization (FISH) techniques use DNA probes to detect pathogens and molecular structures in cells. More recently flow cytometry techniques and other cell capture devices allow lab professionals to select targeted cells that can be further analyzed with PCR, sequencing and mass spectrometry.
"Fastest-growth technologies will be CTC testing and tissue microarrays," said Bruce Carlson, Publisher of Kalorama Information. "Flow cytometry and in situ hybridization will demonstrate more stable growth. The specific market sizes and growth projections for each technology are detailed in the market analysis chapter."
The growing number of cancer patients is a major factor, but a number of technological advancements also contribute to the growth. Sample preparation of histology samples has always been fairly automated, but companies have invested to improve upon this with new faster tissue fixatives and systems that improve nucleic acid extraction from tissue samples. Of note is new instrumentation to automate RNA detection in fixed tissues. This is important for advanced tissue-based pharmacodiagnostic testing.
Agilent, BD, Qiagen, Abbott, Beckman Coulter, Roche and Illumina are among the top companies in the market.
More information is provided in Kalorama Information's The Market for Molecular Histology and Cytology. More information can be obtained at: http://www.kaloramainformation.com/redirect.asp?progid=88264&productid=9590042.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/report-molecular-tissue-and-cell-based-testing-a-25-billion-dollar-market-300204926.html
SOURCE Kalorama Information